ContributorsPublishersAdvertisers

Greater Tolerability Is Seen With Iberdomide in Multiple Myeloma

targetedonc.com
 2021-10-03

Cover picture for the articleResults from CC-220-MM-001 trial support further research of iberdomide-based regimens in multiple myeloma that investigators hope will lead to phase 3 randomized trials and eventual FDA approval of iberdomide in these combinations. When combined with daratumumab (Darzalex), bortezomib (Velcade), or carfilzomib (Kyprolis), iberdomide (CC-220) showed efficacy and tolerability in...

www.targetedonc.com

Comments / 0

Comments / 0